Navigation Links
PBS-Bio uncovers how Unibioscreen drug kills cancer
Date:3/9/2011

MESA, Ariz. March 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.


'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen partner, PBS-Bio, makes first breakthrough drug analysis
2. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
3. New Research Uncovers Elusive Target of Antifungal Agent
4. Purdue-IU team uncovers potential prostate cancer marker
5. Research uncovers extensive natural recovery after spinal cord injury
6. UCLA team uncovers mechanism behind organ transplant rejection
7. Quest for designer bacteria uncovers a Spy
8. Research uncovers a secret society connecting through the Internet
9. Research Uncovers Clue to SIDS
10. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
11. Cognitive Skills May Shrink With Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: